
NYT’s Thomas Friedman; Dr. Scott Gottlieb; Sports Fan Fans
As Covid-19 cases continue to rise in the U.S. Dr. Scott Gottlieb discusses drug treatment distribution and potential supply issues. The New York Times columnist and Pulitzer Prize winning journalist ...
12 Okt 202037min

Lloyd Blankfein on Stimulus and Break-Ups; the NFL & a New Covid Test
Lloyd Blankfein, former chairman and CEO of Goldman Sachs, joins for an extended interview to discuss the stalemate over more federal stimulus, more federal aid for airlines, the state of the bank sec...
9 Okt 202037min

Covid Treatments & Emergency Use Approvals; Debating to Convince “The Undecideds”
Regeneron and Eli Lilly have both asked the FDA to grant their experimental Covid-19 antibody treatments emergency use approval. President Trump, who received Regeneron’s antibody cocktail in his own ...
8 Okt 202037min

Big Tech with Steve Ballmer; U.S. Energy with Chevron CEO
LA Clippers Chairman and former Microsoft CEO Steve Ballmer discusses the prospect of breaking up tech giants after the House Judiciary Antitrust Subcommittee released its 450 page report on Facebook,...
7 Okt 202032min

Awaiting Stimulus with Southwest Airlines CEO & Chef Marcus Samuelsson
After the President’s return to the White House, CNBC’s Eamon Javers discusses containment, messaging, and recovery in the West Wing. Pandemic-bruised airlines await a federal bailout, but Southwest A...
6 Okt 202039min

President Trump’s Condition: Regeneron CEO and Dr. Scott Gottlieb on POTUS Treatment
President Trump remains at Walter Reed National Military Medical Center, and treatments for his coronavirus diagnosis include an experimental antibody cocktail from Regeneron, dexamethasone, and Gilea...
5 Okt 202037min

Testing Positive: Coronavirus Contact Tracing at the White House
President Donald Trump and First Lady Melania Trump have tested positive for the coronavirus, prompting further economic and political uncertainty just 32 days before Election Day. Former FDA Commissi...
2 Okt 202025min

Unpacking Palantir’s Public Debut: CEO Alex Karp
The high profile, highly controversial Palantir has finally gone public on the NYSE after 17 years of near-secret operation. CEO Alex Karp shares the company’s journey to this point, its pathway to pr...
1 Okt 202030min





















